经皮微波热凝固治疗周围型非小细胞肺癌的临床研究  

Percutaneous microwave coagulation for treating peripheral non-small-cell lung cancer

作　　者：孔令德[1,2] 刘海波[2] 陈志涛[2] 肖伟[2] 蔺玉霞[2] 陈颖[2] 朱良明[2] 

机构地区：[1]潍坊医学院,山东省潍坊市261053 [2]山东大学附属济南市中心医院胸外科

出　　处：《中国肿瘤临床》2013年第21期1314-1317,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:评价经皮微波热凝固(percutaneous microwave coagulation therapy,PMCT)治疗周围型非小细胞肺癌的临床价值。方法:总结了2004年3月至2006年9月期间接受经皮微波热凝固疗法的35例非小细胞肺癌患者,并选择同期性别相同、年龄相近、病理类型相同、临床分期相同的放疗患者35例作为对照,观察其疗效进行临床疗效评估,采用Kaplan-Meier法计算生存率,Log-rank检验比较两种方式的生存差异。结果:接受微波热凝固治疗患者的1、3、5年生存率分别为71.4%(25/35)、40.0%(14/35)、20.0%(7/35),接受放射治疗的1、3、5年生存率分别为51.4%(18/35)、22.9%(8/35)、11.4%(4/35),差异有统计学意义(P<0.05)。结论:经皮微波热凝固疗法对因心肺功能差而不能常规手术或恐惧手术创伤的周围型非小细胞肺癌患者是一种微创、安全、有效的好方法。Objective： To evaluate the clinical value ofpercutaneous microwave coagulation therapy for peripheral non-small-cell lung cancer. Methods： We evaluated 35 patients with non-small-cell lung cancer who received percutaneous microwave coagulation therapy and 35 patients who received radiotherapy from March 2004 to September 2006; the patients were sex-matched, age-matched, and had the same pathology and clinical staging. Clinical effects were observed and assessed. Survival rate were calculated using the Kaplan - Meier method. The difference in survival rate between the two treatment methods was analyzed using a log-rank test. Results： The 1-year, 3-year, and 5-year survival rates for the microwave coagulation therapy group （71.4%, 40.0%, and 20.0%, respectively） were significantly higher than those for the radiation therapy （51.4%, 22.9%, and 11.4%, respectively） （P〈0.05）. Conclusion： Percutaneous microwave coagulation therapy is a minimally invasive, safe, and effective alternative for patients with peripheral non-small-cell lung cancer who cannot undergo routine surgery because of poor heart and lung function or fear of surgical trauma.

关 键 词：肺肿瘤 经皮微波热凝固 生存期 

分 类 号：R734.2[医药卫生—肿瘤]